Analysis of the Role of Female Hormones During Infection by COVID-19
Open Access
- 21 December 2021
- journal article
- review article
- Published by Georg Thieme Verlag KG in RBGO Gynecology & Obstetrics
- Vol. 43 (12), 940-948
- https://doi.org/10.1055/s-0041-1740208
Abstract
Women have metabolic, immunological, and genetic variables that ensure more protection from coronavirus infection. However, the indication of treatment for several pathologies and contraception is determined by hormones that have adverse effects and raise doubts about their use during the COVID-19 pandemic. Therefore, the present study searches women specificities and the relation between female sexual hormones and COVID-19, and reports the main recommendations in this background. To this end, a review of the literature was conducted in the main databases, auxiliary data sources, and official websites. Therefore, considering the hypercoagulability status of COVID-19, the debate about the use of contraceptives due to the relative risk of thromboembolic effects that they impose arises. However, the current available evidence, as well as the recommendations of main health organs around the world, demonstrate that the use of hormonal contraceptives must be maintained during the pandemic. As mulheres possuem variáveis metabólicas, imunológicas e genéticas que conferem maior proteção à infecção pelo coronavírus. Todavia, a indicação de tratamento para certas patologias e para a contracepção é determinada por hormônios que possuem efeitos adversos e levantam dúvidas quanto ao seu uso durante a pandemia da COVID-19. Desta forma, o presente estudo busca investigar as especificidades da mulher e a relação dos hormônios sexuais femininos com a COVID-19, assim como relatar as principais recomendações neste contexto. Para isso, realizou-se uma revisão da literatura nas principais bases de dados, fontes auxiliares de dados e sites oficiais. Portanto, considerando o estado hipercoagulável da COVID-19, surge o debate quanto à utilização de contraceptivos pelo seu risco relativo de efeitos tromboembólicos. No entanto, as atuais evidências disponíveis, assim como as recomendações dos principais órgãos de saúde do mundo, demonstraram que o uso de contraceptivos hormonais deve ser mantido durante a pandemia. Received: 12 October 2020 Accepted: 31 August 2021 Publication Date: 21 December 2021 (online) © 2021. Federação Brasileira de Ginecologia e Obstetrícia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Thieme Revinter Publicações Ltda. Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, BrazilKeywords
This publication has 46 references indexed in Scilit:
- Risk prediction of developing venous thrombosis in combined oral contraceptive usersPLOS ONE, 2017
- Sex-Based Differences in Susceptibility to Severe Acute Respiratory Syndrome Coronavirus InfectionThe Journal of Immunology, 2017
- Oral Contraceptives and HRT Risk of ThrombosisClinical and Applied Thrombosis/hemostasis, 2017
- Venous Thromboembolism Due to Oral Contraceptive Intake and Spending Nights in a Vehicle -A Case from the 2016 Kumamoto Earthquakes-Internal Medicine, 2017
- Absorção e metabolização dos hormônios sexuais e sua transformação em tecnologias contraceptivas: percursos do pensamento médico no BrasilCiencia & Saude Coletiva, 2017
- Hormonal contraception and thrombosisFertility and Sterility, 2016
- Drospirenone‐containing combined oral contraceptives and the risk of arterial thrombosis: a population‐based nested case‐control studyBJOG: An International Journal of Obstetrics and Gynaecology, 2016
- Impact of estrogen type on cardiovascular safety of combined oral contraceptivesContraception, 2016
- Sex differences in immune responsesNature Reviews Immunology, 2016
- Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: cohort studyBMJ, 2016